Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, . . . Negar N. Alami. (2023). Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19. Wiley.
Citazione stile Chigago Style (17a edizione)Mohamad Shebley, et al. Phase 1 Study of Safety, Pharmacokinetics, and Antiviral Activity of SARS‐CoV‐2 Neutralizing Monoclonal Antibody ABBV‐47D11 in Patients with COVID‐19. Wiley, 2023.
Citatione MLA (9a ed.)Mohamad Shebley, et al. Phase 1 Study of Safety, Pharmacokinetics, and Antiviral Activity of SARS‐CoV‐2 Neutralizing Monoclonal Antibody ABBV‐47D11 in Patients with COVID‐19. Wiley, 2023.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.